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delineated the BP 3 times, every time with an interval of 2 
weeks. A detailed statistical analysis was performed on 4 
subregions of the BP. The first region extends from the exit 
of the BP through the intervertebral foramina until the 
entrance of the scalene opening. The second region ends at 
the entrance between the subclavius and serratus anterior 
muscles. The third region was defined between the 
subclavius and serratus anterior muscles. The fourth region 
defines the BP bordered between the minor pectoral, 
subscapular and serratus anterior muscles. The delineation 
accuracy was determined by measuring the BP inclusion of 
the delineations on rigidly fused CT-MRI datasets. 
Results: A low inter- and intraobserver reliability was 
observed. The mean inter- and intraobserver kappa was 
respectively 0.29 and 0.45. The minimum and maximum 
Jaccard index in the intraobserver group was 0.004 and 0.636 
while in the interobserver group 0 and 0.124 was obtained. 
The total agreement volume in both intra- and interobserver 
groups was much lower than the union volume. The overall 
accuracy was poor, with an average inclusion of 38% (Figure 
1) . The accuracy of the delineations reduced from the 
medial to the lateral BP regions. 
Conclusions: Poor inter- and intraobserver reliability of the 
RTOG-endorsed BP contouring guidelines was observed. 
Accuracy analysis showed an average BP inclusion of 38%. BP 
inclusion reduced from the medial to the lateral BP regions. 
Insufficient accuracy and reliability of the RTOG-endorsed BP 
guidelines was observed. 
 
 
Table 1 RTOG-endorsed brachial plexus contouring guidelines 
 
Figure 1 Delineation of the brachial plexus (BP) by one 
observer on a cadaver dataset. In this example the 
delineation shows a 38.43% BP (yellow) inclusion. The defined 
subregions: region 1: green, region 2: red, region 3: blue, 
region 4: orange.  
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Purpose/Objective: Radiotherapy is a critical treatment for 
both medulloblastoma and ependymoma. The literature does 
not assess whether or not to include the roots of posterior 
fossa cranial nerves (CN’s - VII-XII) in the target volume. 
There is also little data describing the anatomy of 
cerebrospinal fluid (CSF) as it follows the roots of these CN’s, 
specifically how far it flows into their respective skull base 
formaniae. The role of MRI, in particular steady-state free 
precession sequences such as FIESTA, in imaging the cisternal 
segments of CN’s, is well described. This study aims to 
determine whether a database of FIESTA images can be used 
to answer this anatomical question and whether this data can 
be used to guide radiotherapy planning.  
Materials and Methods: A database of 97 FIESTA sequences 
of the posterior fossa was reviewed. Examinations were 
excluded for these reasons; sagittal reconstructions only, 
abnormal head shape/anatomy, no FIESTA sequences, limited 
number of slices pulled from archive, structure not clearly 
visualized. Measurements were made on the following 
number of scans for each foramen respectively; 86 left 
internal acoustic meatus (IAM), 84 right IAM, 83 left jugular 
foramen (JF), 85 right JF, 42 left hypoglossal canal (HC), 45 
right HC. A protocol was written to describe how 
measurements should be taken. One author, a senior trainee 
in radiation oncology (observer 1), measured all available 
images. Another, a consultant neuro-radiologist (observer 2), 
measured distances for the first 5 patients on the database 
giving 30 data points for comparative analysis. 
Results: Measurements of the HC were difficult and 
unreliable therefore only measurements of IAM and JF were 
used for comparison between 2 observers. The mean 
distances for observers 1 and 2 respectively were 12.4mm 
and 12.0mm (IAM) and 8.0mm and 7.8mm (JF). Differences 
between measurements were normally distributed; a Band-
Altmann analysis was used to assess agreement. A bias of 
+0.3mm was found for observer 1 relative to observer 2. The 
95% confidence interval for disagreement was -0.4mm to 
1.05mm; this was felt to be clinically acceptable. The mean 
distances of CSF flow in the sample were 12.2mm (95% CI 8.8 
– 15.6mm) for IAM and 7.3mm (95% CI 4.0 – 10.6mm) for JF. 
The distribution of data for the HC was bimodal with peaks 
around 2-4mm and 8-10mm, precluding useful analysis. This 
was because many scans stopped around or just beyond the 
HC’s, resulting in poor image quality. We surmise that longer 
measurements come from scans where the HC was fully 
included. 
Conclusions: FIESTA MRI gives excellent views of the 
posterior fossa CN foraminae and the CSF within. 
Measurement of these spaces is robust and reproducible. We 
intend to use these data to analyse previous treatment plans 
for both medulloblastoma and ependymoma and investigate 
whether specific voluming of these structures has any impact 
on target coverage and whether the CSF in these spaces may 
have been under-treated.  
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Purpose/Objective: READY (REsearch program in Auto 
Delineation sYstem)-LUNG01 is an hypothesis-generating 
prospective study, which has the aim to validate in clinical 
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setting the reliability of a pre-release commercial algorithm 
for lung target volumes automatic segmentation for 
Stereotactic body radiation therapy (SBRT) and 4D radiation 
therapy (4DRT). 
Materials and Methods: 20 patients with histologically 
proven lung lesions between 2010 and 2014 (primitive or 
secondary) treated at our Institution with SBRT or 3D 
conformal Radiotherapy (3DCRT) were retrospectively 
collected. 
-13 patients with primary lung cancers or lung metastases (9 
patients with stage I lung cancer, 3 patients with lung 
metastases from rectal adenocarcinoma).  
-7 patients with locally-advanced-lung-cancer stage II-III were 
also selected to test the software with larger volumes. 
-Nodal Volumes were not taken into consideration 
Two Radiation Oncologists (RO) expert in lung cancers agreed 
the delineation of the lung lesions (Master Contour, MC). 
Two different RO performed the Automatic Delineation (AD) 
of the same lesions using the beta version of the 
SmartSegmentation-Knowledge-Based-Contouring 13.5, 
Varian Medical Systems. 
The 2 expert RO edited the automatic contour after a month, 
drawing Edited Delineation (ED). 
The obtained contours (AD and ED) were compared to MC. 
Comparisons were made in terms of geometrical overlap, by 
analyzing: 
Mean Dice-Similarity-Index (mDSI), Mean-Slicewise-Hausdorff-
Distances (MSHD) and Volume difference (cc). 
Results: The analysis of the contouring settings showed: 
1) MC vs AD: mean mDSI=0.78 (1SD±0.13); a MSHD=13.48mm 
(1SD±13.92) and a mean volume difference=4.06cc 
(1SD±18.94). 
2) MC vs ED mean mDSI=0.83 (SD±0.08); a MSHD=2.27mm 
(SD±3.39) and a mean volume difference=6.65cc (SD±18.89). 
When comparing the two groups a statistically significant 
greater concordance between MC vs ED than MC vs AD for DSI 
(p=0.0046) and for MSHD (p 
A qualitative analysis showed that for the early 
stages/metastases lesions qui lo leverei the software had a 
good performance (fig 1). The most significant differences 
between the 2 contours were have been observed at the lung 
bases, when lesions are close to the hepatic dome, and with 
hilum nodules due to structures isodensity. 
 
 
Conclusions: The tested autosegmentation software seems 
promising in the automatic delineation of lung lesions both 
for SBRT or 4DRT purposes and for 3DCRT in more advanced 
stages, offering an acceptable overlap with expert drawn 
contours, although human expert revision is always 
warranted. 
Investigations are ongoing on a larger number of patients to 
define a benchmark for early stage tumor/metastases and for 
locally advanced stages. 
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Purpose/Objective: The prognosis of patients with stage II-III 
non-small cell lung cancer (NSCLC) treated with concurrent 
chemoradiation (CCRT) remains poor. Tumour response 
monitoring over the course of CCRT with 18F-
fluorodeoxyglucose (FDG) PET/CT has the potential to adapt 
the radiation therapy plan to biological parameters. Frequent 
FDG PET/CT scanning, however, is associated with radiation 
exposure to the patient and personnel involved in daily 
treatment. We therefore designed and implemented a weekly 
PET/CT scan protocol using a low dose FDG. The aim of this 
evaluation concerned logistics, safety and patient burden of 
using weekly low dose FDG PET/CT during CCRT. 
Materials and Methods: Stage II-III NSCLC patients with no 
previous malignancies within the last 3 years, scheduled for 
24 x 2.75 Gy with daily low dose cisplatin, were eligible for 
inclusion. Five weekly PET/CT scans (Philips Gemini Big Bore 
ToF) of the tumour and regional lymph nodes in treatment 
position were made over the course of treatment (just before 
each fraction) and at 3 months after CCRT, each with 50 MBq 
FDG, a total scan time of 14 minutes, and two bed positions. 
The image quality of the PET/CT scans was evaluated visually 
and by signal-to-noise levels. The radiation exposure was 
assessed for patients and for staff. Finally, the logistics of 
the procedures in all involved departments was evaluated. 
Results: Thirteen patients were included of which ten 
completed the treatment and imaging course. A patient 
example is given in figure 1. One patient was excluded 
because a different radiotherapy scheme was chosen due to 
dose constraints, one patient demonstrated progressive 
disease on the PET/CT in week 1 and received altered 
treatment, and one patient found the extra imaging too 
demanding. The image quality of low dose FDG PET at 
baseline and during treatment was visually identical to 
routine diagnostic procedures, and had similar resolution and 
signal-to-noise levels. The radiation exposure of patients was 
about 20 mSv for the six scans in total. Following training on 
handling of radioactive patients in the departments of 
radiation oncology and medical oncology, involved staff did 
not receive a significant radiation dose (estimated < 1µSv per 
treatment). Planning logistics of 6 PET/CT scans linked to 
CCRT required close collaboration and dedicated imaging 
time slots. Patients typically spend 1.5 hours longer in 
hospital on days of PET/CT scans. 
 
